CD301b+ monocyte-derived dendritic cells mediate resistance to radiotherapy
Journal of Experimental Medicine · 02.06.2025 · 222 (6)
DOI: 10.1084/jem.20231717 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Experimental Medicine, online erschienen am 27.03.2025. Verfasst von Sirimuvva Tadepalli und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA. Hauptthemen laut MEDLINE: Dendritic Cells, Monocytes, Radiation Tolerance. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Life Sciences Research Foundation, NIH HHS, National Institute of Health.
Abstract (Originalsprache)
Monocytes infiltrating tumors acquire various states that distinctly impact cancer treatment. Here, we show that resistance of tumors to radiotherapy (RT) is controlled by the accumulation of monocyte-derived dendritic cells (moDCs). These moDCs are characterized by the expression of CD301b and have a superior capacity to generate regulatory T cells (Tregs). Accordingly, moDC depletion limits Treg generation and improves the therapeutic outcome of RT. Mechanistically, we demonstrate that granulocyte–macrophage colony-stimulating factor (GM-CSF) derived from radioresistant tumor cells following RT is necessary for the accumulation of moDCs. Our results unravel the immunosuppressive function of moDCs and identify GM-CSF as an immunotherapeutic target during RT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA.
- Immunology Program, Stanford University School of Medicine , Stanford, CA, USA.
- Department of Radiation Oncology, Molecular Imaging Program at Stanford, Stanford University School of Medicine, Stanford, CA, USA.
- Stanford Medical Scientist Training Program, Stanford University School of Medicine , Stanford, CA, USA.
- Department of Nephrology, University Hospital Regensburg, Regensburg, Germany.
- Department of Pharmacology, University of California San Diego School of Medicine, San Diego, CA, USA.
ORCID-Profile: Sirimuvva Tadepalli, Derek R Clements, Hayley M Raquer-McKay, Anja Lüdtke, Sanjana Saravanan, David Seong, Lorraine Vitek, Christopher M Richards, Jan E Carette, Matthias Mack, Andres Gottfried-Blackmore, Edward E Graves, Juliana Idoyaga
Förderung
- Life Sciences Research Foundation
- NIH HHS
- National Institute of Health
- Canadian Institute of Health Research
- Stanford Medicine
- Stanford University
- National Science Foundation Graduate Research Fellowship Program
- NCI NIH HHS
Zitieren
APA
Tadepalli, S., Clements, D. R., Raquer-McKay, H. M., Lüdtke, A., Saravanan, S., Seong, D., Vitek, L., Richards, C. M., Carette, J. E., Mack, M., Gottfried-Blackmore, A., Graves, E. E., & Idoyaga, J. (2025). CD301b+ monocyte-derived dendritic cells mediate resistance to radiotherapy. Journal of Experimental Medicine, 222(6). https://doi.org/10.1084/jem.20231717
Vancouver
Tadepalli S, Clements DR, Raquer-McKay HM, Lüdtke A, Saravanan S, Seong D, et al. CD301b+ monocyte-derived dendritic cells mediate resistance to radiotherapy. Journal of Experimental Medicine. 2025;222(6). doi:10.1084/jem.20231717
BibTeX
@article{Tadepalli2025,
author = {Tadepalli, Sirimuvva and Clements, Derek R and Raquer-McKay, Hayley M and Lüdtke, Anja and Saravanan, Sanjana and Seong, David and Vitek, Lorraine and Richards, Christopher M and Carette, Jan E and Mack, Matthias and Gottfried-Blackmore, Andres and Graves, Edward E and Idoyaga, Juliana},
title = {CD301b+ monocyte-derived dendritic cells mediate resistance to radiotherapy},
journal = {Journal of Experimental Medicine},
year = {2025},
volume = {222},
number = {6},
doi = {10.1084/jem.20231717}
}
EUVIMED